Profil
Peter Herbrechtsmeier currently works at Novartis Venture Fund, as Board Member.
Dr. Herbrechtsmeier also formerly worked at EyeSense GmbH, as Chief Executive Officer from 2003 to 2009 and Ciba Holding AG, as Vice President.
Postes actifs de Peter Herbrechtsmeier
| Sociétés | Poste | Début |
|---|---|---|
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Directeur/Membre du Conseil | - |
Anciens postes connus de Peter Herbrechtsmeier
| Sociétés | Poste | Fin |
|---|---|---|
EyeSense GmbH
EyeSense GmbH Electronic Equipment/InstrumentsElectronic Technology Develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients | Président | - |
Ciba Holding AG
Ciba Holding AG Chemicals: Major DiversifiedProcess Industries Manufactures and distributes chemicals, pigments, adhesives, sealants, paints, coatings, plastics and resins | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Ciba Holding AG
Ciba Holding AG Chemicals: Major DiversifiedProcess Industries Manufactures and distributes chemicals, pigments, adhesives, sealants, paints, coatings, plastics and resins | Process Industries |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Finance |
EyeSense GmbH
EyeSense GmbH Electronic Equipment/InstrumentsElectronic Technology Develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients | Electronic Technology |
















